NEW YORK--(BUSINESS WIRE)--Sep 13, 2018--Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Global Blood Therapeutics, Inc. (NASDAQ: GBT) resulting from allegations that Global Blood may have issued materially misleading business information to the investing public.

On September 13, 2018, Stat  published an article describing “important risks that investors might be glossing over” regarding Global Blood’s FDA approval prospects for its new drug to treat sickle cell disease, voxelotor. The article cited the results of a recent Phase 3 clinical trial and stated “Global Blood lacks data demonstrating voxelotor reduces the frequency of crises,” which is traditionally a necessary criterion for FDA approval of a sickle cell disease treatment. The article further stated that, “[i]n the Phase 3 study, voxelotor did not improve the quality of life of sickle cell patients.” On this news, Global Blood’s share price fell $3.40 per share or over 7.4% to close at $42.55 per share on September 13, 2018.

Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Global Blood investors. If you purchased shares of Global Blood please visit the firm’s website at to join the class action. You may also contact Phillip Kim or Zachary Halper of Rosen Law Firm toll free at 866-767-3653 or via email at or

Follow us for updates on LinkedIn: or on Twitter:

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013.

Attorney Advertising. Prior results do not guarantee a similar outcome.

View source version on

CONTACT: Laurence Rosen, Esq.

Phillip Kim, Esq.

Zachary Halper, Esq.

The Rosen Law Firm, P.A.

275 Madison Avenue, 34thFloor

New York, NY 10016

Tel: 212-686-1060

Toll Free: 866-767-3653

Fax: 212-202-3827



SOURCE: The Rosen Law Firm, P.A.

Copyright Business Wire 2018.

PUB: 09/13/2018 06:16 PM/DISC: 09/13/2018 06:15 PM